Citations

Clear

3138 citation(s) found for "Smith, AM".

Examining the effectiveness of a lower back exoskeleton in reducing discomfort and workload in vascular surgery
Wang, Tianke , Tetteh, Emmanuel , Smith, Tianqi Gao, Mendes, Bernardo C. , Tetteh, Emmanuel , Norasi, Hamid , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 28, 2022 | Volume: 66 | Issue: 1 | Pages: 2153-2157

10.1177/1071181322661169 Get It

Musculoskeletal disorders and intraoperative pain are prevalent among vascular surgeons which can negatively affect their surgical performance and quality of life. The effectiveness of a lower back support exoskeleton to reduce discomfort of the back, subjective fatigue, and the workload associated with performing vascular surgery was evaluated, as well as the participants’ intraoperative upper body postures. Three vascular surgeons were asked to rate their discomfort and fatigue before, during and after performing surgery, and their subjective workload post-operatively. Inertial measurement units (IMUs) were used to measure their intraoperative body postures. No significant differences were found between exoskeleton and baseline discomfort, fatigue, workload, or intraoperative postures. This indicates that although the exoskeleton did not restrict the vascular surgeons’ postures, this exoskeleton was ineffective at reducing their discomfort or workload. Future studies with exoskeletons specifically designed for healthcare applications may show more efficacy in reducing the ergonomic risks to surgeons.
Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease
Rocca, Walter A. , Rocca, Liliana Gazzuola , Savica, Rodolfo , Gazzuola Rocca, Liliana, Smith, Carin Y. , Mielke, Michelle M.

Mayo Clinic

JAMA Network Open | October 26, 2022 | Volume: 5 | Issue: 10 | Pages: e2238663

10.1001/jamanetworkopen.2022.38663 | PMID 36287560 Get It

ImportanceThe association of premenopausal bilateral oophorectomy with parkinsonism and Parkinson disease (PD) remains controversial.ObjectiveTo assess whether women who underwent premenopausal bilateral oophorectomy were at increased risk of parkinsonism and PD and whether the associations varied by age at oophorectomy and by receipt of estrogen replacement therapy.Design, Setting, and ParticipantsThis cohort study used data from a combination of 2 independent cohort studies, the Mayo Clinic Cohort Study of Oophorectomy and Aging 1 and 2, which were based on the Rochester Epidemiology Project medical records–linkage system. A population-based sample of 5499 women from Olmsted County, Minnesota, were included; of those, 2750 women underwent bilateral oophorectomy for a benign indication before spontaneous menopause between January 1, 1950, and December 31, 2007 (oophorectomy cohort), and 2749 age-matched women who did not undergo bilateral oophorectomy were randomly sampled from the general population (reference cohort). Data were analyzed from March 1 to April 30, 2022. The date of oophorectomy was considered the index date for both groups.ExposuresMedical record documentation of bilateral oophorectomy abstracted from a medical records–linkage system (Rochester Epidemiology Project).Main Outcomes and MeasuresIncidence and risk of parkinsonism or PD, with diagnoses confirmed by in-person examination or medical record review.ResultsAmong 5499 participants (median [IQR] age, 45.0 [40.0-48.0] years; 5312 [96.6%] White), 2750 women (2679 White [97.4%]) underwent bilateral oophorectomy at a median age of 45.0 years (IQR, 40.0-48.0 years), and 2749 women (2633 White [95.8%]) with a median age of 45.0 years (IQR, 40.0-48.0 years) at the index date were included in the reference cohort. Bilateral oophorectomy was associated with an increased risk of parkinsonism overall (hazard ratio [HR], 1.59; 95% CI, 1.02-2.46) and in women younger than 43 years at oophorectomy (HR, 7.67; 95% CI, 1.77-33.27). There was a pattern of increasing risk with younger age at the time of oophorectomy using 4 age strata (≥50 years: HR, 1.43 [95% CI, 0.50-4.15]; 46-49 years: HR, 1.55 [95% CI, 0.79-3.07]; 40-45 years: HR, 1.36 [95% CI, 0.64-2.89]; <40 years: HR, 8.82 [95% CI, 1.08-72.00]; P = .02 for trend). The number needed to harm was 53 women overall and 27 women younger than 43 years at the time of oophorectomy. Bilateral oophorectomy was also associated with an increased risk of PD in women younger than 43 years at oophorectomy (HR, 5.00; 95% CI, 1.10-22.70), with a number needed to harm of 48 women. Among women who underwent oophorectomy at 45 years and younger, the risk was lower in women who received estrogen after the procedure and through age 50 years compared with women who did not. For parkinsonism, the HRs were 1.72 (95% CI, 0.54-5.53) vs 2.05 (95% CI, 0.80-5.23); for PD, the HRs were 1.53 (95% CI, 0.29-8.23) vs 2.75 (95% CI, 0.84-9.04). However, the differences were not significant.Conclusions and RelevanceIn this study, premenopausal women who underwent bilateral oophorectomy before age 43 years had an increased risk of parkinsonism and PD compared with women who did not undergo bilateral oophorectomy. These findings suggest that a reduction in the practice of prophylactic bilateral oophorectomy in premenopausal women at average risk of ovarian cancer may have substantial benefit for reducing the risk of parkinsonism and PD.
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial
Khan, Aliya , Rubin, Mishaela R. , Schwarz, Peter , Vokes, Tamara , Shoback, Dolores , Palermo, Andrea , Marcocci, Claudio , Clarke, B.L. , Abbott, Lisa G, Hofbauer, Lorenz C. , Kohlmeier, Lynn, Pihl, Susanne, An, Xuebei, Eng, Walter Frank, Ukena, Jenny, Sibley, Christopher T. , Shu, Aimee D , Khan, Aliya A , Gagnon, Claudia , Palermo, Andrea , Marcocci, Claudio , Clarke, Bart L , Shu, Aimee D , Hofbauer, Lorenz C , Schwarz, Peter , Smith, Alden Raymond , Rejnmark, Lars

Mayo Clinic

Journal of Bone and Mineral Research | October 21, 2022 | Volume: 38 | Issue: 1 | Pages: 14-25

10.1002/jbmr.4726 | PMID 36271471 Get It

ABSTRACT Conventional therapy for hypoparathyroidism consisting of active vitamin D and calcium aims to alleviate hypocalcemia but fails to restore normal parathyroid hormone (PTH) physiology. PTH replacement therapy is the ideal physiologic treatment for hypoparathyroidism. The double-blind, placebo-controlled, 26-week, phase 3 PaTHway trial assessed the efficacy and safety of PTH replacement therapy for hypoparathyroidism individuals with the investigational drug TransCon PTH (palopegteriparatide). Participants (n = 84) were randomized 3:1 to once-daily TransCon PTH (initially 18 μg/d) or placebo, both co-administered with conventional therapy. The study drug and conventional therapy were titrated according to a dosing algorithm guided by serum calcium. The composite primary efficacy endpoint was the proportion of participants at week 26 who achieved normal albumin-adjusted serum calcium levels (8.3–10.6 mg/dL), independence from conventional therapy (requiring no active vitamin D and ≤600 mg/d of calcium), and no increase in study drug over 4 weeks before week 26. Other outcomes of interest included health-related quality of life measured by the 36-Item Short Form Survey (SF-36), hypoparathyroidism-related symptoms, functioning, and well-being measured by the Hypoparathyroidism Patient Experience Scale (HPES), and urinary calcium excretion. At week 26, 79% (48/61) of participants treated with TransCon PTH versus 5% (1/21) wiplacebo met the composite primary efficacy endpoint (p < 0.0001). TransCon PTH treatment demonstrated a significant improvement in all key secondary endpoint HPES domain scores (all p < 0.01) and the SF-36 Physical Functioning subscale score (p = 0.0347) compared with placebo. Additionally, 93% (57/61) of participants treated with TransCon PTH achieved independence from conventional therapy. TransCon PTH treatment normalized mean 24-hour urine calcium. Overall, 82% (50/61) treated with TransCon PTH and 100% (21/21) wiplacebo experienced adverse events; most were mild (46%) or moderate (46%). No study drug-related withdrawals occurred. In conclusion, TransCon PTH maintained normocalcemia while permitting independence from conventional therapy and was well-tolerated in individuals with hypoparathyroidism. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). Abstract TransCon PTH is an investigational once-daily prodrug providing sustained release of active PTH designed to maintain stable PTH levels in the physiological range for 24 hours/day. The PaTHway trial met all primary and key secondary endpoints with statistically significant differences from placebo. Most adverse events (AEs) were mild/moderate. Injection-site reactions and headaches were the most common treatment-related AEs.
Context Analysis of Continued Citation of Retracted Manuscripts Published in Anesthesiology Journals
Frasco, Peter E. , Murray, Andrew W. , Khurmi, Narjeet , Mueller, Jeff T., Poterack, Karl A. , Smith, Bradford B. , Murray, Andrew W.

Mayo Clinic

Anesthesia & Analgesia | October 21, 2022 | Volume: 135 | Issue: 5 | Pages: 1011-1020

10.1213/ane.0000000000006195 | PMID 36269987 Get It

The continued citation of retracted publications from the medical literature is a well-known and persistent problem. We describe the contexts of ongoing citations to manuscripts that have been retracted from a selection of anesthesiology journals. We also examine how bibliographic databases and publisher websites document the retracted status of these manuscripts. The authors performed an analysis of retracted publications from anesthesiology journals using the Retraction Watch database. We then examined how the retraction information was displayed on bibliographic databases, search engines, and publisher websites. The primary outcome was the context of continued citation after retraction of flawed publications within the specialty of anesthesiology. Secondary outcomes included comparison of the documentation, bibliographic databases, search engines, and publisher websites used in identifying the retracted status of these publications and provision of access to the respective retraction notices. A total of 245 original publications were retracted over a 28-year period from 9 anesthesiology journals. PubMed, compared to the other databases and search engines, was the most consistent (98.8%) in documenting the retracted status of the publications examined, as well as providing a direct link to the retraction notice. From the 211 publications retracted before January 2020, there were 1307 postretraction citations accessed from Scopus. The median number of postretraction citations was 3.5 (range, 0–88, with at least 1 citation in 164 publications) in Scopus. Of the postretraction citations, 80% affirmed the validity of the retracted publications, while only 5.2% of citations acknowledged the retraction or misconduct. In 10.2% of the citations from original research studies, retracted manuscripts appeared to influence the decision to pursue or the methods used in subsequent original research studies. The frequency of citation of the 15 most cited retracted publications declined in a similar pattern during the 10 years after retraction. Citation of manuscripts retracted from anesthesiology journals remains a common occurrence. Technological innovations and application of standards for handling retracted publications, as suggested by coalitions of researchers across the spectrum of scientific investigation, may serve to reduce the persistence of this error.
Automated scoring of total inflammation in renal allograft biopsies
Smith, Byron H. , Grande, Joseph P. , Ryan, Maggie, Đenić, Aleksandar , Park, Walter D. , Kremers, Walter K. , Stegall, Mark D. , Smith, Byron , Grande, Joseph, Denic, Aleksandar , Park, Walter , Stegall, Mark D , Kremers, Walter K , Smith, Maxwell L. , Hermsen, Meyke

Mayo Clinic

Clinical Transplantation | October 19, 2022 | Volume: 37 | Issue: 1 | Pages: No page available

10.1111/ctr.14837 | PMID 36259615 Get It

AbstractBackgroundComputer‐assisted scoring is gaining prominence in the evaluation of renal histology; however, much of the focus has been on identifying larger objects such as glomeruli. Total inflammation impacts graft outcome, and its quantification requires tools to identify objects at the cellular level or smaller. The goal of the current study was to use CD45 stained slides coupled with image analysis tools to quantify the amount of non‐glomerular inflammation within the cortex.MethodsSixty renal transplant whole slide images were used for digital image analysis. Multiple thresholding methods using pixel intensity and object size were used to identify inflammation in the cortex. Additionally, convolutional neural networks were used to separate glomeruli from other objects in the cortex. This combined measure of inflammation was then correlated with rescored Banff total inflammation classification and outcomes.ResultsIdentification of glomeruli on biopsies had high fidelity (mean pixelwise dice coefficient of .858). Continuous total inflammation scores correlated well with Banff rescoring (maximum Pearson correlation .824). A separate set of thresholds resulted in a significant correlation with alloimmune graft loss.ConclusionsAutomated scoring of inflammation showed a high correlation with Banff scoring. Digital image analysis provides a powerful tool for analysis of renal pathology, not only because it is reproducible and can be automated, but also because it provides much more granular data for studies.
Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors
Thibord, Florian , Klarin, Derek , Brody, Jennifer A. , Chen, Ming‐Huei , Levin, Michael G. , Chasman, Daniel I. , Goode, Ellen L. , Teder‐Laving, Maris , Martínez-Pérez, Ángel , Daian-Bacq, Delphine, Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L. , Nadkarni, Girish N. , Vries, Paul S. de , Wolford, Brooke N. , Pattee, Jack , Brækkan, Sigrid K. , Li‐Gao, Ruifang , Saut, Noémie , Sept, Corriene, Judy, Renae , O’Donnell, Christopher J. , Giulianini, Franco, Boland, Anne , Empana, Jean‐Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Zhou, Wei , Soria, José Manuel , Souto, Juan Carlos , Haessler, Jeffery, Hindberg, Kristian , Bartz, Traci M. , Heckbert, Susan R. , Armasu, Sebastian M. , Brumpton, Ben , Smadja, David M. , Jouven, Xavier , Loos, Ruth J. F. , Sabater‐Lleal, Maria , Pankow, James S. , Reiner, Alex P. , Vlieg, Astrid van Hylckama , Deleuze, Jean-François, Skogholt, Anne Heidi , Emmerich, Joseph , Tang, Weihong , Jackson, Rebecca D. , Hansen, John‐Bjarne , Morange, Pierre‐Emmanuel , Kabrhel, Christopher , Johnson, Andrew D. , Smith, Nicholas L. , Martinez-Perez, Angel , Aïssi, Dylan , Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L , Nadkarni, Girish N , de Vries, Paul S , Wolford, Brooke N , Kooperberg, Charles , Braekkan, Sigrid K , Li-Gao, Ruifang , Saut, Noemie , Germain, Marine , Wiggins, Kerri L , Ko, Darae , O'Donnell, Christopher J , Taylor, Kent D , de Andrade, Mariza , Nøst, Therese H , Boland, Anne , Empana, Jean Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Manuel Soria, Jose , Carlos Souto, Juan , Pankratz, Nathan , Rosendaal, Frits R , Turman, Constance , Olaso, Robert , Bartz, Traci M , Lynch, Julie A , Heckbert, Susan R , Brumpton, Ben , Smadja, David M , Komuro, Issei , Clapham, Katharine R , Loos, Ruth J F , Willer, Cristen J , Sabater-Lleal, Maria , Pankow, James S , Reiner, Alexander P , Ridker, Paul M. , Rader, Daniel J , Min Lee, Kyung , Psaty, Bruce M , Rich, Stephen S , Vy, Ha My T , Tang, Weihong , Damrauer, Scott M , Johnson, Andrew D , Smith, Nicholas L , Chasman, Daniel I , Brody, Jennifer A , Hveem, Kristian , Cuéllar-Partida, Gabriel , Kooperberg, Charles , Germain, Marine , Wiggins, Kerri L. , Taylor, Kent D. , Andrade, Mariza de , Koyama, Satoshi , Huffman, Jennifer E. , Pankratz, Nathan , Turman, Constance , Kember, Rachel L. , Lynch, Julie A. , Morelli, Vânia Maris , Deleuze, Jean‐François , Kraft, Peter , Lee, Kyung Min , Psaty, Bruce M. , Suchon, Pierre , Rich, Stephen S. , Trégouët, David‐Alexandre

Mayo Clinic

Circulation | October 17, 2022 | Volume: 146 | Issue: 16 | Pages: 1225-1242

10.1161/circulationaha.122.059675 | PMID 36154123 Get It

Background: Venous thromboembolism (VTE) is a life-threatening vascular event with environmental and genetic determinants. Recent VTE genome-wide association studies (GWAS) meta-analyses involved nearly 30 000 VTE cases and identified up to 40 genetic loci associated with VTE risk, including loci not previously suspected to play a role in hemostasis. The aim of our research was to expand discovery of new genetic loci associated with VTE by using cross-ancestry genomic resources. Methods: We present new cross-ancestry meta-analyzed GWAS results involving up to 81 669 VTE cases from 30 studies, with replication of novel loci in independent populations and loci characterization through in silico genomic interrogations. Results: In our genetic discovery effort that included 55 330 participants with VTE (47 822 European, 6320 African, and 1188 Hispanic ancestry), we identified 48 novel associations, of which 34 were replicated after correction for multiple testing. In our combined discovery-replication analysis (81 669 VTE participants) and ancestry-stratified meta-analyses (European, African, and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. A genetic risk score of the significantly associated loci in Europeans identified a 6-fold increase in risk for those in the top 1% of scores compared with those with average scores. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein quantitative-trait locus Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 GWAS loci provided insights to biological pathways contributing to VTE, with some loci contributing to VTE through well-characterized coagulation pathways and others providing new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. Conclusions: Our cross-ancestry GWAS meta-analyses identified new loci associated with VTE. These findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of improved antithrombosis treatments.
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
Krysiak, Kilannin , Danos, Arpad , McMichael, Joshua F. , Coffman, Adam , Kiwala, Susanna , Sheta, Lana , Kujan, Lynzey , Pema, Shahil , Ridd, Sarah , Spies, Nicholas C. , Andric, Veronica , Chiorean, Andreea , Rieke, Damian , Clark, Kaitlin A., Reisle, Caralyn , Venigalla, Ajay C, Jani, Payal , Takahashi, Hideaki , Suda, Avila, Horak, Peter , Ritter, Deborah , DeLong, Sean , Lamping, Mario , Shen, Haolin , Marr, Alexander , Hoang, My , Singhal, Kartik , Khanfar, Mariam , Li, Brian V , Lin, Wan‐Hsin , Terraf, Panieh, Corson, Laura , Salama, Yasser, Farncombe, Kirsten M. , Ji, Jianling , Zhao, Xiaonan, Xu, Xinjie , Kanagal‐Shamanna, Rashmi , Walker, Jason , Zhang, Jinghui , Patel, Ronak Y. , Kim, Raymond H. , Jones, Steven J.M. , Raca, Gordana , Madhavan, Subha , Griffith, Malachi , Griffith, Obi L. , Coffman, Adam C , Kiwala, Susanna , Zhou, Xin , Campbell, Katie M , Ji, Jianling , Cotto, Kelsy C , Schriml, Lynn M , Wagner, Alex H , Griffith, Malachi , Griffith, Obi L , Krysiak, Kilannin , Kanagal-Shamanna, Rashmi , Kim, Raymond H , Saliba, Jason , Barnell, Erica K. , Grisdale, Cameron J. , Lever, Jake , Venigalla, Ajay , Evans, Mark G. , Ainscough, Benjamin J. , Kesserwan, Chimene A. , Zhao, Xiaonan, King, Ian F. G. , Skidmore, Zachary L. , Milosavljevic, Aleksandar , Giles, Rachel H. , Mardis, Elaine R. , Rao, Shruti , Wagner, Alex H. , Khanfar, Mariam

Mayo Clinic

Nucleic Acids Research | October 15, 2022 | Volume: 51 | Issue: D1 | Pages: D1230-D1241

10.1093/nar/gkac979 | PMID 36373660 Get It

Abstract CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence Items) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new Evidence Types (Predisposing, Oncogenic and Functional). The growing CIViC knowledgebase has over 300 contributors and distributes clinically-relevant cancer variant data currently representing >3200 variants in >470 genes from >3100 publications.
NCCN Guidelines® Insights: Survivorship, Version 1.2022
Sanft, Tara , Peterson, Lindsay L. , Rodriguez, Maria Alma , Ansbaugh, Shannon, Demark‐Wahnefried, Wendy , Dickinson, Kristin , Fairman, Nathan, Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Khakpour, Nazanin , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Porpiglia, Andrea S., Ruddy, Kathryn J. , Schapira, Lidia , Shockney, Lillie D. , Syrjala, Karen L. , Yang, Eric H. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Broderick, Gregory, Henry, N Lynn , Yang, Eric , Demark-Wahnefried, Wendy , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Ballinger, Tarah Jean , Broderick, Gregory A. , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , O’Connor, Tracey L. , Overholser, Linda , Paskett, Electra D. , Pirl, William F. , Smith, Sophia K. , Tevaarwerk, Amyé

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 14, 2022 | Volume: 20 | Issue: 10 | Pages: 1080-1090

10.6004/jnccn.2022.0052 | PMID 36240847 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals who work with survivors to ensure that the survivors’ complex and varied needs are addressed. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for the consequences of adult-onset cancer and its treatment; recommendations to help promote physical activity, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.
Inspiratory and leg muscle blood flows during inspiratory muscle metaboreflex activation in heart failure with preserved ejection fraction
Hammer, Shane M. , Bruhn, Eric J., Bissen, Thomas G. , Muer, Jessica, Villarraga, Nicolas , Olson, Thomas P. , Smith, Joshua R. , Muer, Jessica D, Smith, Joshua R , Borlaug, Barry A.

Mayo Clinic

Journal of Applied Physiology | October 13, 2022 | Volume: 133 | Issue: 5 | Pages: 1202-1211

10.1152/japplphysiol.00141.2022 | PMID 36227167 Get It

Respiratory muscle dysfunction is thought to contribute to exercise intolerance in heart failure with preserved ejection fraction (HFpEF); however, the underlying mechanisms are unknown. In the present study, patients with HFpEF had greater increases in leg muscle vascular resistance index and greater decreases in leg muscle blood flow index compared with controls during inspiratory resistive breathing (to activate the metaboreflex). Furthermore, respiratory muscle blood flow index responses normalized to pressure generation during inspiratory resistive breathing were exaggerated in HFpEF compared with controls.
Suppression and Replacement Gene Therapy for KCNH2 -Mediated Arrhythmias
Bains, Sahej , Zhou, Wei , Dotzler, Steven M. , Martinez, Katherine , Kim, CS John, Tester, David J. , Ye, Dan , Ackerman, Michael J. , Bains, Sahej , Ye, Dan

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 13, 2022 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/circgen.122.003719 | PMID 36252106 Get It

Background: KCNH2 -mediated arrhythmia syndromes are caused by loss-of-function (type 2 long QT syndrome [LQT2]) or gain-of-function (type 1 short QT syndrome [SQT1]) pathogenic variants in the KCNH2 -encoded K v 11.1 potassium channel, which is essential for the cardiac action potential. Methods: A dual-component “suppression-and-replacement” (SupRep) KCNH2 gene therapy was created by cloning into a single construct a custom-designed KCNH2 short hairpin RNA with ~80% knockdown (suppression) and a “short hairpin RNA-immune” KCNH2 cDNA (replacement). Induced pluripotent stem cell-derived cardiomyocytes and their CRISPR-Cas9 variant-corrected isogenic control (IC) induced pluripotent stem cell-derived cardiomyocytes were made for 2 LQT2- (G604S, N633S) and 1 SQT1- (N588K) causative variants. All variant lines were treated with KCNH2-SupRep or non-targeting control short hairpin RNA (shCT). The action potential duration (APD) at 90% repolarization (APD 90 ) was measured using FluoVolt voltage dye. Results: KCNH2-SupRep achieved variant-independent rescue of both pathologic phenotypes. For LQT2-causative variants, treatment with KCNH2-SupRep resulted in shortening of the pathologically prolonged APD 90 to near curative (IC-like) APD 90 levels (G604S IC, 471±25 ms; N633S IC, 405±55 ms) compared with treatment with shCT (G604S: SupRep-treated, 452±76 ms versus shCT-treated, 550±41 ms; P <0.0001; N633S: SupRep-treated, 399±105 ms versus shCT-treated, 577±39 ms, P <0.0001). Conversely, for the SQT1-causative variant, N588K, treatment with KCNH2-SupRep resulted in therapeutic prolongation of the pathologically shortened APD 90 (IC: 429±16 ms; SupRep-treated: 396±61 ms; shCT-treated: 274±12 ms). Conclusions: We provide the first proof-of-principle gene therapy for correction of both LQT2 and SQT1. KCNH2-SupRep gene therapy successfully normalized the pathologic APD 90 , thereby eliminating the pathognomonic feature of both LQT2 and SQT1.